Amicus Therapeutics Inc. (NASDAQ:FOLD) saw an upside of 10.53% to close Tuesday at $13.86 after adding $1.32 on the day. The 5-day average trading volume is 2,995,000 shares of the company’s common stock. It has gained $13.87 in the past week and touched a new high 3 times within the past 5 days. An average of 2,947,510 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,524,282.
FOLD’s 1-month performance is 14.45% or $2.08 on its low of $11.73 reached on 07/10/23. The company’s shares have touched a 52-week low of $9.10 and high of $13.85, with the stock’s rally to the 52-week high happening on 08/08/23. YTD, FOLD has achieved 13.51% or $1.65 and has reached a new high 7 times. However, the current price is up 0.07% from the 52-week high price.
Insider Transactions
FOLD stock investors last saw insider trading activity on Aug 01.Campbell Bradley L (President & CEO) most recently sold 20,000 shares at $13.39 per share on Aug 01. This transaction cost the insider $267,874. Executive Chairman, Crowley John F, sold 6,044 shares at a price of $13.35 on Aug 01. Then, on Jul 17, Executive Chairman Crowley John F sold 6,044 shares at a price of $13.45 per share. This transaction amounted to $81,263.
Valuation Metrics
FOLD stock has a beta of 0.86. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 11.94 while the price-to-book (PB) in the most recent quarter is 39.60.
Amicus Therapeutics Inc.’s quick ratio for the period ended March 30 was 2.70, with the current ratio over the same period at 2.90. As well, the company’s long term debt to equity for the quarter ending March 30 was 3.83, while the total debt to equity was 3.83.. In terms of profitability, the gross margin trailing 12 months is 88.70%. The trailing 12-month EBITDA margin is -60.47% while for the period ending March 30, Amicus Therapeutics Inc.’s operating margin was -51.80%. The firm’s gross profit as reported stood at $290.63 million against revenue of $329.23 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Amicus Therapeutics Inc.’s cash and short-term investments amounted to $106.51 million against total debt of $452.01 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -61.08% to -$52.93 million, while revenue of -$55.87 million was -5.55% off the previous quarter. Analysts expected FOLD to announce -$0.15 per share in earnings in its latest quarter, but it posted -$0.18, representing a -20.00% surprise. EBITDA for the quarter stood at more than -$35.71 million. FOLD stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 597.95 million, with total debt at $452.01 million. Shareholders hold equity totaling $284.58 million.
Let’s look briefly at Amicus Therapeutics Inc. (FOLD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 60.68% to suggest the stock is trending Neutral, with historical volatility in this time period at 61.56%.
The stock’s 5-day moving average is $13.30, reflecting a +3.36% or $0.45 change from its current price. FOLD is currently trading +15.02% above its 20-day SMA, +21.26% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +24.42% and SMA200 by+29.17%.
Stochastic %K and %D was 40.49% and 33.92% and the average true range (ATR) pointed at 0.56. The RSI (14) points at 59.74%, while the 14-day stochastic is at 99.39% with the period’s ATR at 0.50. The stock’s 9-day MACD Oscillator is pointing at -0.19 and -0.25 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Amicus Therapeutics Inc. (NASDAQ: FOLD), Morgan Stanley launched coverage with an Equal-weight rating. Analysts offering their rating for FOLD stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate FOLD as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is FOLD’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $20.00, with their median price target at $16.00. Looking at these predictions, the average price target given by analysts is for Amicus Therapeutics Inc. (FOLD) stock is $15.90.
